

Renee,

A few questions for an article I am working on:

Does the prescription drug data on Bloomberg, provided by Symphony, fairly portray Wellbutrin XL prescription trends in Valeant's opinion?

From the second quarter to the third quarter last year, Valeant's reported revenues from Wellbutrin XL jumped over 37%. The math doesn't add up (vol x avg price).

What explains this differential?

Does Valeant still stand by its statement to Bloomberg reporters that the Direct Success channel accounts for under 5% of the drugs sales?

Wellbutrin XL, off patent for years, is at 25% of peak sales when most generics for the likes of Pfizer settle in around 3% (Zoloft is at 13% after years of effort and tens of millions of marketing dollars).

How?

Per Bloomberg data, the Days Sales Outstanding (DSO) for Valeant appears higher than rivals Merck and AGN.

Is there a comment Valeant wishes to make about this?

At the 12/16/2015 analyst meeting in Newark, CEO Pearson spoke about "bringing down the inventories in the wholesale channel," "the continued impact of the reduction in channel inventories" and referenced getting "normalized in 2016."

Does Valeant have a stuffed channel re: its inventories

After the Congressional hearing CEO Howard Schiller flew the G6 back to Morristown airport. Was anyone concerned about the optics of that viz. the hearing about price gouging?

CEO Schiller has three times flown the G6--the world's most expensive private jet--for an apparent ski house he owns in the Breckenridge area. Is this personal jet use board approved?